Amit Ajay, Dikhit Manas R, Pandey Raj K, Singh Kuljit, Mishra Ritesh, Das V N R, Das Pradeep, Bimal Sanjiva
Division of Immunology, Rajendra Memorial Research Institute of Medical Sciences, Patna, 800007, India.
Department of Biotechnology, National Institutes of Pharmaceutical Education and Research, Hajipur, 844102, India.
PLoS One. 2016 May 17;11(5):e0154117. doi: 10.1371/journal.pone.0154117. eCollection 2016.
Serum adenosine deaminase (ADA) activity increases in diseases where cellular immunity is involved. Since cell-mediated immune responses play a paramount role in the pathogenesis and healing of the visceral leishmaniasis, therefore, the present study was undertaken to evaluate the serum ADA activity in different pathological conditions. Adenosine deaminase was determined in sera of active visceral leishmaniasis (VL) patients (n = 39), active postkala-azar dermal leishmaniasis (PKDL) cases (n = 34) at the point of diagnosis and after treatment stages along with healthy controls (n = 30), endemic healthy subjects (n = 34) and endemic asymptomatic subjects (n = 34).Our in-vitro result revealed that monocytes secrete significant ADA level in response to Leishmania donovani (L.donovani) stimulation. The serum ADA activity in active VL and PKDL subjects were found to be significantly higher than that of respective treated cases and healthy controls. We also observed a marginal number (17.6%) of endemic asymptomatic subjects showed elevated serum ADA activity. Further, the ADA activity in PKDL was found to be decreased gradually during the different phases of treatment. Interestingly, 2 out of 32 treated VL cases found to have high serum ADA activity during follow up period were relapsed within few days. These results suggest the possibility of ADA as a marker of clinical pathogenesis and can be used as a surrogate marker in the diagnosis and prognosis of VL and PKDL.
血清腺苷脱氨酶（ADA）活性在涉及细胞免疫的疾病中会升高。由于细胞介导的免疫反应在内脏利什曼病的发病机制和愈合过程中起着至关重要的作用，因此，本研究旨在评估不同病理状况下的血清ADA活性。对活动性内脏利什曼病（VL）患者（n = 39）、活动性黑热病后皮肤利什曼病（PKDL）患者在诊断时和治疗后的血清进行了ADA测定，同时纳入了健康对照者（n = 30）、地方性健康受试者（n = 34）和地方性无症状受试者（n = 34）。我们的体外实验结果显示，单核细胞在杜氏利什曼原虫（L.donovani）刺激下会分泌显著水平的ADA。发现活动性VL和PKDL受试者的血清ADA活性显著高于各自的治疗后病例和健康对照者。我们还观察到有少量（17.6%）地方性无症状受试者的血清ADA活性升高。此外，发现PKDL患者在治疗的不同阶段ADA活性逐渐降低。有趣的是，在32例接受治疗的VL病例中，有2例在随访期间血清ADA活性较高，且在数天内复发。这些结果表明ADA有可能作为临床发病机制的标志物，并可作为VL和PKDL诊断及预后的替代标志物。
